BRPI0409321A - antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo - Google Patents

antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo

Info

Publication number
BRPI0409321A
BRPI0409321A BRPI0409321-6A BRPI0409321A BRPI0409321A BR PI0409321 A BRPI0409321 A BR PI0409321A BR PI0409321 A BRPI0409321 A BR PI0409321A BR PI0409321 A BRPI0409321 A BR PI0409321A
Authority
BR
Brazil
Prior art keywords
antigen
hybrid
inducing
immune response
infectious
Prior art date
Application number
BRPI0409321-6A
Other languages
English (en)
Inventor
Jessica Baker Flechtner
Kenya Prince-Cohane
Sunil Mehta
Paul Slusareqicz
Sofija Andjelic
Brian H Barber
Original Assignee
Antigenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/776,521 external-priority patent/US7420037B2/en
Priority claimed from US10/820,067 external-priority patent/US7309491B2/en
Application filed by Antigenics Inc filed Critical Antigenics Inc
Publication of BRPI0409321A publication Critical patent/BRPI0409321A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"ANTìGENO HìBRIDO, COMPOSIçãO E MéTODO PARA INDUZIR UMA RESPOSTA IMUNE PARA UM AGENTE INFECCIOSO OU ANTìGENO DE TUMOR, MéTODO PARA TRATAR UMA DOENçA INFECCIOSA OU CáNCER, E, PEPTìDEO". Antígenos híbridos compreendendo pelo menos um domínio antigênico, pelo menos um domínio de ligação de proteína de choque térmico, e pelo menos um ligador de peptídeo melhorado no meio são descritos que são utilizáveis para a indução de uma resposta imune ao domínio antigênico quando administrados sozinhos ou em um complexo com pelo menos uma proteína de choque térmico. Os antígenos híbridos e complexos podem ser usados para tratar doenças infecciosas e cânceres que expressam um antígeno do domínio antigênico.
BRPI0409321-6A 2003-04-11 2004-04-09 antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo BRPI0409321A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US46246903P 2003-04-11 2003-04-11
US46374603P 2003-04-18 2003-04-18
US50341703P 2003-09-16 2003-09-16
US10/776,521 US7420037B2 (en) 2003-02-13 2004-02-12 Heat shock protein-based vaccines and immunotherapies
PCT/US2004/004340 WO2004071457A2 (en) 2003-02-13 2004-02-13 Improved heat shock protein-based vaccines and immunotherapies
US10/820,067 US7309491B2 (en) 2003-04-11 2004-04-08 Heat shock protein-based vaccines and immunotherapies
PCT/US2004/010983 WO2004091493A2 (en) 2003-04-11 2004-04-09 Improved heat shock protein-based vaccines and immunotherapies

Publications (1)

Publication Number Publication Date
BRPI0409321A true BRPI0409321A (pt) 2006-05-23

Family

ID=35539709

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409321-6A BRPI0409321A (pt) 2003-04-11 2004-04-09 antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo

Country Status (8)

Country Link
EP (1) EP1617804A4 (pt)
JP (1) JP2007525448A (pt)
KR (1) KR20050121721A (pt)
AU (1) AU2004229458B2 (pt)
BR (1) BRPI0409321A (pt)
CA (1) CA2521809A1 (pt)
MX (1) MXPA05010881A (pt)
WO (1) WO2004091493A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2538794C (en) * 2003-09-12 2016-04-19 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
CA2605321A1 (en) 2005-04-19 2006-10-26 Eli Lilly And Company Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
CY1112212T1 (el) * 2008-04-24 2015-12-09 Immatics Biotechnologies Gmbh Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
EP2113253B1 (en) * 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
EP2734231A1 (en) * 2011-07-21 2014-05-28 Biotech Tools S.A. Dosage of dnak
EA201792501A1 (ru) * 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
IL123218A0 (en) * 1995-08-18 1998-09-24 Sloan Kettering Inst Cancer Heat shock protein-based vaccines and immunotherapies
IL135860A0 (en) * 1997-10-31 2001-05-20 Sloan Kettering Inst Cancer Conjugate heat shock protein-binding peptides
CA2406472A1 (en) * 2000-04-17 2001-10-25 James E. Rothman Javelinization of protein antigens to heat shock proteins
US20040071656A1 (en) * 2001-12-26 2004-04-15 Felix Wieland Modulation of heat-shock-protein-based immunotherapies
US7420037B2 (en) * 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies

Also Published As

Publication number Publication date
WO2004091493A3 (en) 2006-04-20
MXPA05010881A (es) 2006-05-31
AU2004229458B2 (en) 2009-11-19
JP2007525448A (ja) 2007-09-06
KR20050121721A (ko) 2005-12-27
EP1617804A2 (en) 2006-01-25
AU2004229458A1 (en) 2004-10-28
WO2004091493A2 (en) 2004-10-28
EP1617804A4 (en) 2007-07-25
CA2521809A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
IL192679A0 (en) Aglyco products and uses thereof
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
DE60044665D1 (de) Her2/neu fusionsproteine
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
ES2154738T3 (es) Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
BR0316758A (pt) Vacinas baseadas em levedura como imunoterapia
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
PL366575A1 (pl) Kompozycje oraz sposoby leczenia i diagnozowania raka jajnika
ATE149841T1 (de) Impfstoffe gegen krebs und infektionskrankheiten
BG101103A (bg) Теломераза при бозайници
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
AR045056A1 (es) Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
BR0207067A (pt) Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo
DE60335186D1 (de) Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
PL343245A1 (en) Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
BR9612619A (pt) Método e composição para reconformar antígenos multiepitópicos para iniciar uma resposta imunológica
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
FI20011671A7 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
WO2000025722A3 (en) ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS
BRPI0409321A (pt) antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo
BR0009781A (pt) Anticorpos antiidiotìpicos contra anticorpos que inibem a ligação de imunoglobulina e ao seu receptor de alta afinidade
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.